Myron Levin, MD

Professional Titles

• Associate Director, Pediatric HIV Clinic

Research Interests

Dr. Levin is studying the immune response to herpes virus infections and methods of treating and preventing such infections, including antiviral therapy and active immunization. He does basic research on the nature of latency of herpes viruses in human neurons. A vaccine to prevent shingles in elderly individuals has been developed and licensed through his clinical research, and further investigations of this vaccine are in progress.

Publications

• Lee KS, Zhou W, Scott-McKean JJ, Emmerling KL, Cai GY, Krah DL, Costa AC, Freed CR, Levin MJ. Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One. 2012;7(12):e53010. PubMed PMID: 23285249
• Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines. 2012 Nov;11(11):1293-303. PubMed PMID: 23151111
• Vermeulen JN, Lange JMA, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Harper C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan ISF, Vessey R, Schödel FP, Annunziato P, Schlienger K, Silber JL. Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine in Healthy Adults = 60 Years of Age. Vaccine 2012; 30: 904-910.
• Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier S-O, Mansi JA, Brisson M. Productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study (Vaccine, 2012, in press).
• Weinberg A, Huang S, Song L-Y, Fenton T, Williams P, Patterson J, Tovar-Salazar A, and Levin M. Immune correlates of herpes zoster in HIV-infected children and youth. (J Virol 2012; 86: 2878-2871.
• Abzug MJ; Qin M, Levin MJ, Fenton T, Beeler JA, Bellini WJ, Audet S, Sowers SB, Borkowsky W, Nachman SA, Pelton SI, Rosenblatt HM, for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity, immunologic memory, and safety following measles re-vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2012; 206: 512-522.
• Tyring SK, Stek JE, Smith JG, Xu J, Pagnoni M, Chan ISF, Silber JL, Parrino J, Levin MJ. Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster (HZ) subjects. Clin Vaccine Immunol 2012; 19: 1411-1415.
• Weinberg A, Song L-Y, Fenton T, Saah A, Brown M, Moscicki AB, Handelsman E, Meyer III WA, Bryan J, Levin MJ. Magnitude and persistence of humoral, mucosal and cell-mediated immunity including cross-reactivity with nonvaccine serotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 2012; 206: 1309-1318.
• Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Current Opinion in Immunology 2012; 24: 494-500.
• Schmader K, Oxman MN, Harbecke R, Levin MJ, Betts R4 Morrison VA, Gelb L, Pachucki C, Keay S, Menzies B, Griffin M, Kaufman C, Marquez A, Toney J, Johnson G, Zhang JH, Li X, Chan ISF , Annunziato P for the Shingles Prevention Study Group. Persistence and durability of herpes zoster vaccine efficacy. (Clin Infect Dis; 2012; 55: 1320-1328.
• Bernstein DI, Stokes-Riner A, Wald A, Hook E, Levin M, Ewell M, Wolff P, Deal C, Heinemann T, Dubin G, Belshe R. Prospective evaluation of primary infection with herpes simplex virus type 1 and type 2 in young women. (Accepted,,Clin Infect Dis 2012).
• Tobeck SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live attenuated influenza vaccine. Expert Rev Vaccines 2012; 11: doi: 10.1586/ERV.12.108.
• Lee KS, Zhou W, Scott-McKean JJ, Cai G-Y, Krah DL, Costa AC, Freed CR, Levin MJ. Human Sensory Neurons Derived from Induced Pluripotent Stem Cells Support Varicella-Zoster Virus Infection. Plos One 2012; 7: e53010.doi:10.1371/journal.pone.0053010.
• Lindsey JC, Shah S, Siberry G, Jean-Philippe P, Levin MJ. Scientific and ethical dilemmas in the design of a clinical trial for HIV-infected adolescents in lower income settings – case study of an HPV vaccine. (Accepted; Bioethics, 2012).
• Irwin MR, Levin MJ, Laudenslager M, Carrillo C, Olmstead R, Lucko A, Lang N, Stanley HA, Caulfield MJ, Weinberg A, Chan ISF, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Johnson G, Oxman MN. Varicella-Zoster Virus Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients with Major Depressive Disorder ( Accepted, CID 2012).265.265.Drolet, M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: State of the evidence. (Accepted; Human Vaccines & Immunotherapeutics, 2013).
• Abzug MJ, Nachman SA, Muresan P, Weinberg A, Handelsman E, Watts H, Fenton T, Heckman B, Petzold E, and Levin MJ, for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1086 Protocol Team. Safety and Immunogenicity of 2009 pH1N1 Vaccination in HIV-Infected Pregnant Women (Accepted; Clin Infect Dis, 2013).
• Drolet M, Oxman MN; Levin MJ,. Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: State of the evidence (Accepted, Human Vaccinews, 2013).
• Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan ISF, Keller PM, Williams HM, Boardman, KD, Annunziato PW, for the Shingles Prevention Study Group. Safety of Zoster Vaccine in Elderly Adults With a Prior Episode of Documented Herpes Zoster. (Accepted, J Infect Dis, 2013).
• Rubin LG, Levin MJ, Ljungman P, Davies G, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. 2011 IDSA clinical practice guideline for immunization of the immunocompromised host. (Clin Infect Dis; 2013)
• Levin MJ, Schmader KE, Gnann JW, Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C, Zhao Y, Li X, Chan ISF, Annunziato PW, Parrino J. Varicella-Zoster virus specific antibody responses in 50-59 year old recipients of herpes zoster vaccine (submitted, J Infect Dis, 2013).
• Frazer IH, Levin MJ. Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Current Opinion in Virology, Section: Vaccines (in press, 2012).
• Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 21st Ed. Lange Medical Books-McGraw –Hill Companies (New York), 2012.
• Dominguez S, Weinberg A, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 21st Ed., Lange Medical Books-McGraw Hill (New York) 2012, pg 1293-1336.
• Levin MJ, Weinberg A: Infections: Chap. 40. Infections: Viral and Rickettsial. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 21st Ed., Lange Medical Books-McGraw Hill (New York) 2012, pg 1177-1219.
• Levin MJ. Zoster Vaccine. In: Plotkin S, Orenstein W, Offitt P, (Eds): Vaccines. 6th Edition, Saunders Elsevier (USA); pg 969-980.
• Lee E, Cho HJ, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep. 2013 Nov 1;36(11):1685-91. PubMed PMID: 24179302
• Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine. 2013 Oct 1;31(42):4782-90. PubMed PMID: 23954381
• Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 1;208(9):1386-90. PubMed PMID: 23908486
• Lindsey JC, Shah S, Siberry G, Jean-Philippe P, Levin MJ. Scientific and ethical dilemmas in the design of a clinical trial for HIV-infected adolescents in lower income settings - case study of an HPV vaccine. Developing World Bioethics 2013; 13: 95-104.
• Irwin MR, Levin MJ, Laudenslager M, et al. Varicella-zoster virus Specific Immune Responses toa Herpes Zoster Vaccine in Elderly Recipients with Major Depressive Disorder. Clin Infect Dis 2013; 56: 1085-93.
• Hull CM, Levin MJ, Tyring SK, Spruance SL. Combination antiviral and anti-inflammatory treatment for recurrent herpes simplex labialis: Rationale and efficacy demonstrated with a novel Composite efficacy measure. Antimicrob Agents Chemother 2014; 58: 1273-8.
• Levin MJ. Varicella in Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Editors: Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatr Infect Dis J 2013; 32 (Supplement 2): 1303-1404. (Access as http://www.aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0).
• 203. Levin MJ. Herpes Simplex in Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Editors: Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatr Infect Dis J 2013; 32: (Supplement 2): 1303-1404. (Access as http://www.aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0).
• Chiu C, McCausland M, Sidney J, Rouphael N, Mehta A, Weinberg A, Levin MJ, Pulendran B, Peters B, Sette A, Ahmed R. Identification of human virus-specific CD8+ T cells recognising a conserved epitope in both ?- and ?-herpesviruses. PLoS Pathogens 2014; e1004008:1-12.
• Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Morris P, Dessy F Giannini S, Descamps D, and Dubin G. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from 2 randomized trials. Vaccine 2014; 32):3694-705.
• Krishnarajah G, Burstin S, Carroll C, Priest J, Arondekar B, Levin M.. Burden of vaccine-preventable disease in adult Medicaid and commercially insured populations: Analysis of claims-based databases, 2006–2010. Human vaccines and immunotherapeutics 2014; 10: 1-8.
• Suaya J, Burstin S, Levin MJ. Incidence of herpes zoster and persistent zoster-associated pain in adults with and without diabetes in the United States. (Open Forum Infectious Diseases 2014 doi: 10.1093/ofid/ofu049.
• Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano E, Salmerón J, Del Rosario-Raymundo R, Angsuwathana S, Vallejos C, Verheijen R, Quek SC, ter Harmsel B, Ferguson L, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Rosen JB, Girard G, Levin MJ, Patricio VM, Chatterjee A, Stapleton J, Chakhtoura N, Martens M, Meijer CJCM, Franco EL, Quint W, David M-P, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G for the VIVIANE Study Group. Efficacy, safety and immunogenicity of HPV-16/18 ASO4-adjuvanted vaccine® in women aged over 25 years: 4-year follow-up of the double-blind, randomised VIVIANE study (Lancet September 2014).
• Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N. Varicella-zoster virus infections in patients treated with fingolimod: Risk assessment and consensus recommendations for management. JAMA Neurol. 2014 (Nov 24) Published online doi:10.1001/jamaneurol.2014.3065.
• Levin MJ. Varicella-Zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol 2014 (in press)
• 284. Arvin AM, Wolinsky JS, Appos LI, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N. Varicella-zoster virus infections in patients treated with fingolimod: Risk assessment and consensus recommendations for management. JAMA Neurology 2015; 72: 31-39
• Abzug MJ, Nachman SA, Muresan P, Weinberg A, Handelsman E, Watts H, Fenton T, Heckman B, Petzold E, Levin MJ. Safety and Immunogencity of 2009 pH1N1 Vaccination in HIV-Infected Pregnant Women. Clin Infect Dis 2013; 56: 1488-97.
• 286. Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T1, Bloom A, Watts DH, Abzug MJ, Nachman SA and Levin MJ for P1086 study team. Determinants of vaccine immunogenicity in HIV-infected pregnant women: Comprehensive analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLos One 2015, e0127062.
• 287. Brown AEC, Asturias EJ, Melgar M; Antillon FA, Mettler P, Levin MJ. Incidence and consequences of varicella in children with cancer in Guatemala (World Journal of Pediatrics, in press, 2015
• 288. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ,. McElhaney JE, Airi Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, for the ZOE-50 Study Group. A phase 3 trial of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-2096.
• Drolet M, Oxman MN, Levin MJ, et al. Vaccination against Herpes Zoster in Developed Countries: State of the Evidence. Human Vaccines & Immunotherapeutics 2013; 9: 1-8.
• 289. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR,. Kauffman CA, Marques A, Toney J, Boardman K, Su S-C, Li X, Chan ISF, Parrino J, Annunziato P, and Oxman MH; for the Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60: 900-909.
• 290. Brown AEC, Cohen MN; Tong S, Braverman RS, Giller R; Levin MJ. Safety and pharmacokinetics of cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. Antimicrob Agents Chemo 2015; 59; 3718-25.
• Morrison VA, Oxman MN, Levin MJ, et al. Safety of Zoster Vaccine in Elderly Adults with Prior a Episode of Documented Herpes Zoster. J Infect Dis 2013; 2018: 559-63.
• 291. Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Paul S, Mcfarland EJ, Weinberg A. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: A retrospective case review. PLos One 2015: 10: e0127062. DMID: 26000984.
• Mirani G, Williams PL, Chernoff M, Abzug MJ, Levin MJ, Seage GR III, Oleske J, Purswani M, Hazra R, Traite S, Zimmer B, and Van Dyke RB for the IMPAACT P1074 Study Teams. Infectious and non-infectious complications and mortality among US youth and young adults with HIV-1 infection in the combination antiretroviral therapy era. J AIDS 2015 (Clin Infect Dis, Accepted press, 2015).
• .Levin M, Schmader K, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su S-C, Parrino J, Popmihajlov Z, Weinberg A. Administration of a Second Dose of Herpes Zoster Vaccine Ten Years After a First Dose. (JID, in press).
• Amaravadi RK, Schilder RJ,. Martin LP, Levin MJ, Graham MA, Weng DE, Adjei AA. A phase 1 study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma (Accepted, Molecular Cancer Genetics, 2015).
• Smith C, Weinberg A, Forster JE, Levin MJ, Davies J5, Pappas J, Kinzie K, Barr E, Paul S, and McFarland EJ. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir (JAIDS, in press).
• Beals CR, Railkar R, Schaeffer A, Levin Y, Meyer B,. Sheldon EA, Lassiter K, Levin MJ. Immune Response and Reactogenicity After Intradermal Administration of Live Herpes Zoster Vaccine (Lancet Infectious Diseases, in press).
• Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva P, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat M-C, Rosillon D, Baril L for the VIVIANE study group. Progression of HPV infection to cervical lesion or clearance in adult women: analysis of the control arm of the VIVIANE study. (in press, International J Cancer)
• 92. Levin MJ. Zoster Vaccine. In: Plotkin S, Orenstein W, Offitt P, (Eds): Vaccines. 6th Edition, Saunders Elsevier (USA);2015:
• Rubin LG, Levin MJ, Ljungman P, et al. 2011 IDSA Clinical Practice Guideline for Immunization of the Immuncompromised Host. Clin Infect Dis (in press)
• Chen S-Y, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, Levin MJ. Incidence of Herpes Zoster in Patients with Altered Immune function. Infection 10, November 2013 online; DOI 1007/s15010-013-0550-8
• Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. J Infect Dis. 2016 Jan 1;213(1):14-22. PubMed PMID: 26452397
• Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM, Bwakura-Dangarembizi M, Ogwu A, Mpabalwani EM, Sato P, Siberry G, Nelson M, Hille D, Weinberg GA, Weinberg A. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS. 2017 Jan 2;31(1):49-59. PubMed PMID: 27662551
• Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Aug;16(8):915-22. PubMed PMID: 27061887
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. PubMed PMID: 27626517
• Smith C, Weinberg A, Forster JE, Levin MJ, Davies J5, Pappas J, Kinzie K, Barr E, Paul S, and McFarland EJ. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir. Infect Dis Obstet Gynecol #9848041 doi: 10.1155/2016/9848041
• Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva P, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat M-C, Rosillon D, Baril L for the VIVIANE study group. Progression of HPV infection to cervical lesion or clearance in adult women: analysis of the control arm of the VIVIANE study. International J Cancer 2015, epub. PMID: 26685704
• Qian L, Chen S-Y, Burstin SJ, Levin MJ, Suaya JA. Cost of herpes zoster in patients with selected immune-compromised conditions in the United States. Open Forum Infectious Diseases 2016; 3 (2): doi: 10.1093/ofid/ofw067.
• Uprety P, Lindsey JC, Levin, MJ, Rainwater-Lovett K, Ziemniak C, Kaplan SA, Nelson M, Zadzilka A, Weinberg A, Persaud D. Inflammation and immune activation in antiretroviral-treated HIV-1-Infected African infants and rotavirus vaccine responses (accepted J Infect Dis 2016).
• Levin MJ, Scott DS, Weinberg A. Herpes Simplex Virus and Varicella-Zoster Virus in Diagnostic Microbiology of the Immunocompromised Host: 2nd Edition, edited by RT Hayden, DM Wolk, KC Carroll, and Y-W Tang. Microbiol Spectrum 4(3):DMIH2- 0017-2015. doi:10.1128/microbiolspec.DMIH2-0017-2015.
• Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 23rd Ed. Lange Medical Books-McGraw –Hill Companies (New York), 2016.
• Levin MJ. Zoster Vaccine. In: Plotkin S, Orenstein W, Offitt P, (Eds): Vaccines. 6th Edition, Saunders Elsevier (USA)
• Levin MJ, Weinberg A, Asturias E: Infections: Chap. 40. Infections: Viral and Rickettsial. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 23nd Ed., Lange Medical Books-McGraw Hill (New York) 2016, pg 1170-1213.
• Dominguez S, Weinberg A, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 22nd Ed., Lange Medical Books-McGraw Hill (New York) 2016, pg 1291-1329.
• Levin MJ, Rehm S. Shedding light on shingles: the power of prevention. http://courses.elseviercme.com/shingles/user/login?destination=node/687
• Levin MJ, Weinberg A: Editorial: Regulatory T cells: Getting It Just Right. Editorial. J Infect Dis 2016; 214; 4-6. PMID: 27117510
• Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal M, Bwakura-Dangarembizi M, Ogwu A, Mpabalwani E, Heckman B, Sato P, Siberry G, Nelson M, Hille D, Weinberg GA, Weinberg A for the IMPAACT P1072 Protocol Team. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with and without HIV infection in Africa. AIDS 2017; 31: 49-58. PMID: 27662551
• Uprety P, Lindsey JC, Levin, MJ, Rainwater-Lovett K, Ziemniak C, Kaplan SA, Nelson M, Zadzilka A, Weinberg A, Persaud D. Inflammation and immune activation in antiretroviral-treated HIV-1-Infected African infants and rotavirus vaccine responses (accepted J Infect Dis 2017)
• Levin MJ, Huang S, Moscicki A, Song L-Y, Read JS, Meyer WA, Saah A, Richardson K, Weinberg A for the IMPAACT P1085 Protocol Team. Four-Year persistence of type-specific immunity after administration of quadrivalent human papillomavirus vaccine to HIV-infected children; Effect of a fourth dose of vaccine. Vaccine 2017; 35: 1712-1720. PMID: 28238631
• Levin MJ. Herpes Simplex. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Gnanashanmugam D, Mofenson LM, Kapogiannis B, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at: https://aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0 . [Updated February, 2017].
• Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whattaker J, Levin MJ. VZV-Specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunology 2017; 199: 604-612. PMID: 28607114.
• Falloon J, Yu J, Esser M, Villfana T, Dubovsky F, Takas T, Levin MJ, Falsey AR An adjuvanted, post-fusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. (in press, J Infect Dis).
• Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine (in press, Vaccine).
• Graybill C, Morgan MJ, Claypool DJ, Levin MJ, Lee KS. Varicella-zoster virus (VZV) infection of ARPE-19 cells as an in vitro model of VZV-induced uveitis (J Infect Dis, accepted 2017).
• Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw K-L, Saddier P, Willis E, Curtis JR. Studies with Herpes Zoster Vaccines in Immune Compromised Patients. Expert Rev Vaccines 2017; 16: 1217-1230. PMID: 29053937.
• Levin MJ, Cai G-Y, Lee KA, Rouphael N, Mehta AK, Mulligan M, Caniff J, Weinberg A. Varicella-zoster virus DNA in blood after administration of herpes zoster vaccine (accepted; J Infect Dis 2017).
• Levin MJ, Scott DS, Weinberg A. Herpes Simplex Virus and Varicella-Zoster Virus in Diagnostic Microbiology of the Immunocompromised Host: 2nd Edition, edited by RT Hayden, DM Wolk, KC Carroll, and Y-W Tang. 2017. Microbiol Spectrum 4(3):DMIH2- 0017-2015. doi:10.1128/microbiolspec.DMIH2-0017-2015.
• Levin MJ, Rehm S. Shedding light on shingles: the power of prevention. http://courses.elseviercme.com/shingles/user/login?destination=node/687.
• Levin MJ. Zoster Vaccines. In: Plotkin S, Orenstein W, Offitt P, Edwards KM (Eds): Vaccines. 7th Edition, Elsevier (USA). 2017: pg 1268-1281.
• Levin MJ, Schmader KS, Oxman MN. Varicella and Herpes Zoster (chapter 170) in Dermatology in general Medicine. 2017:
• Levin MJ, Weinberg A, Asturias E, Olson D: Infections: Chap. 40. Infections: Viral and Ricketsial In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 24th Ed., Lange Medical Books-McGraw Hill (New York) 2018.
• Dominguez S, Weinberg A, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 24th Ed., Lange Medical Books-McGraw Hill (New York) 2018.
• Hay WW, Levin MJ, Deterding RR, Abzug MJ, Sondheimer J (eds): Current Pediatric Diagnosis & Treatment, 24th Ed. Lange Medical Books-McGraw–Hill Companies (New York), 2018.
• Levin MJ, Albrecht M. Herpes Zoster, Post TW, ed. UpToDate, Waltham, MA. UpToDate Inc. http://www.uptodate.com. accessed
• Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L; Volpi A, Heineman T. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine, 2018;36(12):1537-1541). PMID: 29463421
• Weinberg A, Lindsey J, Bosch R, Lawrence J, Nelson M, Persaud D, Sato P, Ogwu A, Asmelash A, Bwakura-Dangarambezi M, Chi B, Heckman B, Zadzilka A, Canniff J, Lockman S, Getsemani S, Moyo S, Smith C, Moraka NO and Levin MJ for the P1072 and Tshipidi study teams. B and T cell subsets associated with antibody responses to the pentavalent rotavirus vaccine in African HIV-exposed infected and uninfected Infants. Frontiers in Immunology 2018 online: https://doi.org/10.3389/firmmu.2017.02002).
• Reisinger KS, Richardson E, Malacaman EA, Levin MJ, Gardner JL, Wang W, Stek JE, Kuter B. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX® (accepted by Vaccine, 2018).
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Andrews C, Athan E, Bergland J, Campora L, deLoose F, Korhonen T, Lal H, Leung E, Levin M, Volpi A, Johnson RW on behalf of the ZOE 50/70 study group. The impact of reactogenicity after the first dose of recombinant zoster vaccine upon the physical functioning and quality of life of older adults: an open phase III trial. (Accepted, J Gerontol A Biol Sci Med Sci 2019).
• Weinberg A, Levin MJ. Immune response to zoster vaccines. Human Vaccines and Immunotherapeutics 2019; 15: 772-777: https://doi.org/10.1080/21645515.
• 330. Oostvogels L. Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P. Zahaf T J, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Herve C, Hwang S-J, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksen K, Smetana J, Watanabe D, Weckx LY, and Cunningham AL for the ZOE-50/70 Study Group. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: A pooled post-hoc analysis of two parallel randomized trials. Vaccine 2019 (in press). https://doi.org/10.1080/21645515.2019.1627818
• 331. Weinberg A, Lambert SL, Canniff J, Li Y, Lang N, Esser MT, Falloon J, Levin MJ. Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. Human Vaccines & Immunotherapeutics 2019; https://doi.org/10.1080/21645515.2019.1589282
• Weinberg A, Huang S, Moscicki A, Saah A, Levin MJ for the IMPAACT P1085 Protocol Team. Persistence of memory B and T cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS 2018 32: 851-860. PMID: 29424778
• Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang S-J, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Hideyuki I, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ for the ZOE-50/70 Study Group. Immune Responses to a recombinant glycoprotein E herpes zoster vaccine in adults. J Infect Dis 2018; 217: 1750-1760. PMID: 29529222.
• Curran D, Andrew MK, Levin MJ, Turriani E, Matthews S, Fogarty C, Kleain NP, Grupping K, Oostvogels L, Schmader K. Evaluation of two frailty indices, with practical application in a vaccine clinical trial. (accepted, Human vaccines & immunotherapeutics, 2019).
• Streifel A, Novin AR, Hawkins KL, Foster C, Bessesen M, Falutz J, Moanna A, Oxman MN, Langness J, Levin MJ, and Erlandson KM. Low rates of vaccination for herpes zoster in older people living with HIV. AIDS Research and Human Retroviruses 2018; 34(7):603-606. PMID: 29661022
• Heineman YH, Cunningham AC, Levin MJ. Expert Reviews: Understanding the immunology of the Shingrix zoster vaccine. Current opinions in immunology 2019; 59:42-48, https://doi.org/10.1016/j.coi.2019.02.009
• Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest 2018; 128: 4429-4440. PMID: 30024861
• Weinberg A, Pang L. Johnson MM, Caldas Y, Cho A, Tovar Salazar A, Canniff J, Schmader K, Popmihajlov, Z, Levin MJ. The effect of age on the Immunogenicity of the live attenuated zoster vaccine correlates with baseline regulatory T cells and VZV-specific T cell immunity. J Virology 2019; 93: e00305-19.
• Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG®) administration up to 10 days following varicella exposure in pregnant women, immunocompromised subjects, and infants: Efficacy and safety results from a large, open-label, expanded-access program. PLoS ONE 14(7): e0217749. https://doi.org/10.1371/journal. pone.0217749.
• Harbecke R, Jensen NJ, Depledge DP. Johnson GR, Ashbaugh ME, Schmid DS, Breuer J, Levin MJ, Oxman MN. Recurrent herpes zoster in the shingles prevention study: Are second episodes caused by the same varicella-zoster virus strain? (accepted Vaccine, 2019).
• Duchon JM, Levin, MJ, Gershon AA. Safety and varicella outcomes in in utero-exposed newborns and preterm infants treated with varicella zoster immune globulin (VARIZIG): A subgroup analysis of an expanded access program. (Accepted, J Pediatric Infectious Diseases Society, 2019).
• Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Canniff J, Cho A, McCarson B, Martin J, Pang L, Levin MJ. Persistence of varicella- zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. (In press, J Infect Dis 2018).
• Levin MJ. Herpes Simplex. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Gnanashanmugam D, Mofenson LM, Kapogiannis B, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at: https://aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0 . [Updated June 2018].
• Cunningham AL, Levin MJ. Herpes Zoster Vaccines.J Infect Dis 2018 (suppl); 2018: S127- S133
• Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, and Levin MJ. Comparative immune responses to licensed herpes zoster vaccines. J Infect Dis 2018 (suppl); S81- S87.
• Graybill C, Morgan MJ, Levin MJ, and Lee KS. Varicella-zoster virus inhibits autophagosome-lysosome fusion and subsequent degradation of mTOR-mediated autophagic flux. (Accepted, Virology, 2018).
• Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J,. Erlandson KM for the VACS Project Team. Herpes zoster and herpes zoster vaccine rates among adults living with and without HIV in the Veterans Aging Cohort Study (Accepted JAIDS, 2018).
• Levin MJ, Weinberg A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine (in press, Clin Infect Dis, 2019)
• Albrecht M, Levin MJ, Clinical manifestations of varicella-zoster virus infection: Herpes zoster. Post TW, ed. UpToDate, Waltham, MA. UpToDate Inc. http://www.uptodate.com. Accessed 1/7/19.
• Albrecht MA, Levin MJ. Epidemiology, clinical manifestations and diagnosis of herpes zoster. Post TW, ed. UpToDate. Waltham, MA, UpToDate Inc. http//www.uptodate.com. Accessed 3/22/19.
• Albrecht MA, Levin MJ. Epidemiology, clinical manifestations and diagnosis of herpes zoster. Post TW, ed. UpToDate. Waltham, MA, UpToDate Inc. http//www.uptodate.com. Accessed 3/22/19.
• Levin MJ, Schmader KS, Oxman MN. Chapter 165. Varicella and herpes zoster in Fitzpatrick’s Dermatology, 9th Edition. Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS (Editors). McGraw-Hill Education (New York, NY) 2019, pg 3035-3064.
• Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed. Lange Medical Books-McGraw–Hill Companies (New York), 2020
• Gaensbauer J, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed., Lange Medical Books-McGraw Hill (New York). 2020, pg XXXX-YYYY.
• 0lson D. Asturias EJ, Levin MJ: Infections: Chap. 40. Infections: Viral and Ricketsial In: Hay WW, Levin MJ, Bunik,M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed., Lange Medical Books-McGraw Hill (New York) 2020, pg XXXX-YYYY.
• Albrecht MA, Levin MJ. Post-exposure prophylaxis against varicella-zoster virus infection. Post TW ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised 11/8/19.
• Levin MJ. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. AIDSinfo https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/419/varicella-zoster-virus. Posted December 6, 2019
• Duchon JM, Levin, MJ, Gershon AA. Safety and varicella outcomes in in utero-exposed newborns and preterm infants treated with varicella zoster immune globulin (VARIZIG): A subgroup analysis of an expanded access program. J pediatric infectious diseases society 2020; 9: 449-453.
• Levin MJ, Weinberg A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin Infect Dis 2020; 70: 1509-1515. PMID: 31618437.
• Kim J, Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Levin M, Oostvogels L, Zahaf T, Schuind A and Cunningham A on behalf of the ZOE-50/70 study group. Post-hoc analysis of reactogenicity trends between Dose 1 and Dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Human vaccines and immunotherapeutics, 2020: 10.1080/21645515.2020.1741312.
• Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A on behalf of the ZOE-50/70 study group. Efficacy and serious adverse event profile of the adjuvanted recombinant zoster in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology
• Meyers JL, Candrilli SD, Rausch DA, Yan S, Krishnarajah G, Patterson BJ, Levin MJ. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine, 2018; 36: 6810-6818. PMID: 30249425.
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Andrews C, Athan E, Bergland J, Campora L, deLoose F, Korhonen T, Lal H, Leung E, Levin M, Volpi A, Johnson RW on behalf of the ZOE 50/70 study group. The impact of reactogenicity after the first dose of recombinant zoster vaccine upon the physical functioning and quality of life of older adults: an open phase III trial. (Accepted, J Gerontol A Biol Sci Med Sci).
• Schmader KS, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Herve C, Grupping K, Schuind AE, Oostvogels L, Curran D. Impact of reactogenicity after two doses of recombinant zoster vaccine upon physical functioning and quality of life: an open phase III trial in older adults (in press, J Gerontology: Medical Sciences, 2020).
• Levin MJ, Kroehl M, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J. Clin Invest 2018; 128: 4429-4440. Doi: 10.1172/JCI121484
• Curran D, Hyung Kim J, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, McNeil SA, Schuind AE, Andrew MK. Recombinant Zoster Vaccine is efficacious and safe in frail individuals. J Am Geriatrc Soc, Nov 16, 2020). https://doi.org/10.1111/jgs.16917.
• Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, and Levin MJ. Comparison antibody responses to the live-attenuated and recombinant herpes zoster vaccines (in press, J Virology, 2020)
• Weinberg A, Levin MJ. Immune response to zoster vaccines. Human Vaccines and Immunotherapeutics 2018; 15: #6 ( in press)
• Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed. Lange Medical Books-McGraw–Hill Companies (New York), 2020
• Gaensbauer J, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed., Lange Medical Books-McGraw Hill (New York). 2020, pg 1236-1299.
• 0lson D. Asturias EJ, Levin MJ: Infections: Chap. 40. Infections: Viral and Ricketsial In: Hay WW, Levin MJ, Bunik,M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed., Lange Medical Books-McGraw Hill (New York) 2020, pg 1178-1224.
• Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: a cohort study of US claims database. 2018 (accepted by Vaccine).
• Albrecht MA, Levin MJ. Post-exposure prophylaxis against varicella-zoster virus infection. Post TW ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised 2/3/20.
• Levin MJ. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. AIDSinfo https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/419/varicella-zoster-virus.
• Johnson RW, Levin MJ. Herpes zoster and its prevention by vaccination. In: Weinberger B (ed): Current Vaccines for the Older Population: Current Practices and Future Opportunities. Interdiscip Topics Gerontol Geriatr. Basel, Karger, 2020; 43: 131-145 (DOI: 10.1159/000504484).
• Cunningham AC, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for the ageing. Brit Med J
• Cunningham A, Johnson RW, Levin M, Weinberg A. Advance and controversies in our understanding of herpes zoster. J Infect Dis Supplementary Volume. 2018; 52: S55 – S132.
• Schmader KS, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Herve C, Grupping K, Schuind AE, Oostvogels L, Curran D. Impact of reactogenicity after two doses of recombinant zoster vaccine upon physical functioning and quality of life: an open phase III trial in older adults. J Gerontology A Biol Sci Med Sci 2021: 76: 485-490
• Curran D, Hyung Kim J, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, McNeil SA, Schuind AE, Andrew MK. Recombinant Zoster Vaccine is efficacious and safe in frail individuals. J Am Geriatrc Soc 2021; 69: 744-752.
• Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. Brit Med J 2021; 372: n188; http://dx.doi/org/10.1136/bmj.n188.
• Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, and Levin MJ. Comparison antibody responses to the live-attenuated and recombinant herpes zoster vaccines. J Virology 2021; 95: e00240-21.
• Callegaro A, Burny W, Hervé C, Kim JH, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine J Infect Dis 2021).
• Anupindi VR, DeKoven M, Divino V, Pelton SI, Levin MJ, Mould-Quevedo J, Postma MJ. A Real-World Clinical and Economic Analysis of Cell-derived Quadrivalent Influenza Vaccine Compared to Standard Egg-derived Quadrivalent Influenza Vaccines During the 2019-20 Influenza Season in the United States (Accepted Vaccine, 2021).
• Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, and Parikh SA. Humoral and cellular immune responses to the recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia or monoclonal B cell lymphocytosis. Am J Hematology.
• Johnson MJ, Liu C, Debashis G, Lang N, Levin MJ, Weinberg A. Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: Five-year persistence. (Accepted, J Infect Dis, 2021).
• Divino V, Anupindi R, DeKoven M, Mould-Quevedo J, Pelton SI, Postma MJ, Levin MJ. A Real-World Clinical and Economic Analysis of Cell-derived Quadrivalent Influenza Vaccine Compared to Standard Egg-derived Quadrivalent Influenza Vaccines During the 2019-20 Influenza Season in the United States. (Accepted Open Forum Infectious Diseases, 2021).
• Oostvogels L. Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P. Zahaf T J, Dagnew A, Chlibek R, Diez-Domingo J, Gorfinkel IS, Herve C, Hwang S-J, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksen K, Smetana J, Watanabe D, Weckx LY, and Cunningham AL for the ZOE-50/70 Study Group. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: A pooled post-hoc analysis of two parallel randomized trials. Vaccine 2018 (accepted for publication).
• Levin MJ, 0lson D. Asturias EJ, Weinberg A: Infections: Chap. 40. Infections: Viral and Ricketsial In: Hay WW, Levin MJ, Deterding RR, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 24th Ed., Lange Medical Books-McGraw Hill (New York) 2018, pg 1187-1232
• Gaensbauer J, Messacar. Dominguez SR, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Deterding RR, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 24th Ed., Lange Medical Books-McGraw Hill (New York) 2018, pg 1311-1350..
• Hay WW, Levin MJ, Deterding RR, Abzug MJ, SondheimerJ (eds): Current Pediatric Diagnosis & Treatment, 24th Ed. Lange Medical Books-McGraw–Hill Companies (New York), 2018.
• Albrecht M, Levin MJ, Clinical manifestations of varicella-zoster virus infection: Herpes zoster. Post TW, ed. UpToDate, Waltham, MA. UpToDate Inc. http://www.uptodate.com.
• 104. Albrecht M, Levin MJ. Treatment of herpes zoster. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Accessed
• Albrecht m, Levin MJ. Epidemiology and pathogenesis of varicella-zoster virus infection, Herpes Zoster. Post TW, ed. UpToDate. Waltham, MA, UpToDate Inc. http//www.uptodate.com. Accessed
• Albrecht m, Levin MJ. Epidemiology and pathogenesis of varicella-zoster virus infection, Herpes Zoster. Post TW, ed. UpToDate. Waltham, MA, UpToDate Inc. http//www.uptodate.com. Accessed
• 107. Cunningham AL, Levin MJ, Heineman TC. Herpes zoster vaccines: What’s new?. Chapter 4 in Vaccinations. Poland GA, Whitaker JA (editors). Elsevier (St. Louis, Mo), 2018
• Albrecht M, Levin MJ. Treatment of herpes zoster in the immunocompetent host. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Accessed July 7, 2021.
• Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed. Lange Medical Books-McGraw–Hill Companies (New York), (in press);
• Albrecht M, Levin MJ. Treatment of herpes zoster in the immunocompetent host. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised and accessed July 27, 2022.
• Bunik M, Hay WH, Levin MJ, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 26th Ed. Lange Medical Books-McGraw–Hill Companies (New York); 2022.
• Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, and Parikh SA. Humoral and cellular immune responses to the recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia or monoclonal B cell lymphocytosis. Am J Hematol 2022; 97: 90-98,. doi:10.1002/ajh.2638
• Johnson MJ, Liu C, Debashis G, Lang N, Levin MJ, Weinberg A. Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: Five-year persistence. J Infect Dis 2022,225: 1477-1481.
• J. Divino V, Anupindi R, DeKoven M, Mould-Quevedo J, Pelton SI, Postma MJ, Levin MJ. A Real-World Clinical and Economic Analysis of Cell-derived Quadrivalent Influenza Vaccine Compared to Standard Egg-derived Quadrivalent Influenza Vaccines During the 2019-20 Influenza Season in the United States. Open forum Infectious Diseases, 2022; https://doi.org/10.1093/ofid/ofab604
• Levin M, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near A, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT on behalf of the PROVENT Study Group. Intramuscular AZD7442 (tixagevimab/cilgavimab) for prevention of COVID-19. NEJM 2022; 386: 2188.
• Ku JH, Levin MJ, Luo Y, Florea A, Lin I-C, Tian Y, Tseng H-F. Risk of severe COVID-19 infection in individuals with Down syndrome: a matched-cohort study from a large, integrated healthcare system. Clin Infect Dis 2022; 226; 757-765.
• Park SY, Levin MJ, Canniff J, Johnson M, Weinberg A. Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. (Clin Infect Dis, in press 2022).
• Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; on behalf of the STORM CHASER Study Group. AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19. (Clin Infect Dis, accepted 2022)
• .Levin MJ. Chapter 6 Zoster Vaccines. In: Plotkin S, Orenstein W, Offitt P, Edwards KM (Eds): Vaccines. 8h Edition, Elsevier (USA). 2022:
• Weinberg A, Schmid DS, Leung J, Johnson MJ, Miao C, Levin MJ. Predictors of five-year persistence of antibody responses to zoster vaccines. J Infect Dis 2023;228:1367-1374.
• Tuffy KM, Ahani B, Aksyuk AA, Avila M, Brady T, Kijak GH, Koh G, Levin MJ, Roe TL, Schuko N, Ustianowski A, Zhang T, Kelly EJ, and Streicher K. Analysis of SARS-CoV-2 variants identified from breakthrough infections in the PROVENT prevention trial of AZD7442 (Tixagevimab/Cilgavimab) J Infect Dis 2023; 228: 1055-1059.
• Janoff EN, Tseng H-F, Nguyen JL, Alfred T, Vietri J, McDaniel A, Chilson E, Yan Q, Malhotra D, Isturiz RE, Levin MJ. Incidence and Clinical Outcomes of Pneumonia in Persons with Down Syndrome in the United States. Vaccine 2023; 41: 4571-4578.
• Laing KJ, Ford ES, Johnson MJ, Levin MJ, Koelle DM, Weinberg A. Recruitment of naïve CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest 2023; e172634; PMID: 37788096
• DeKoven M, Divino V, Levin MJ, Mould-Quevedo J, Pelton SI, Postma MJ, Zhou Z. A Clinical and Economic Assessment of Adjuvanted Trivalent Versus Standard Egg-Derived Quadrivalent Influenza Vaccines Among Older Adults in the United States During the 2018-19 and 2019-20 Influenza Seasons (in press)
• Bunik M, Levin MJ, Abzug MJ. Schreier T (eds): Current Pediatric Diagnosis & Treatment, 27th Ed., Lange Medical Books-McGraw Hill (New York) 2023 (in press).
• Albrecht M, Levin MJ. Treatment of herpes zoster in the immunocompetent host. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised and accessed September 27, 2023.

Professional Memberships

• Infectious Diseases Society of America, Fellow
• Pediatric Infectious Disease Society, Fellow

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation

• Children's Hospital Colorado
• University of Colorado Hospital

Specialty Information

Specialties

• Internal Medicine, Board Certification (1979)
• Infectious Disease, Board Certification (1996)

Conditions & Treatments

• Infections - Viral Infections
• Infections - Sexually Transmitted Diseases
• Immune System - AIDS
• Immune System - AIDS / HIV Disease
• Immune System
• Infections